Mural Oncology

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Wall Street

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

MURA

PDYN

SCLX

SGMT

VITL

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Stock market analysts

ASPI

CURB

MNSO

TNDM

This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

workday shutter2

Movers

AIRI

BENF

ELAB

MNTS

NITO

PIXY

PMNT

PRTG

PTWO

RRGB

RZLV

SATL

SQNS

STAF

SVMH

WDAY

WIMI

Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Mural Oncology PLC

Murakami Corp

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments PLC

MURATA MFG INC ORD by Murata Manufacturing Inc.

Murata Manufacturing Co Ltd

MURATA MFG INC UNSP/ADR by Murata Manufacturing Inc.

Press Releases

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology to Participate in Two Upcoming Investor Conferences

Earnings

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Aadi Bioscience

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Agenus

Aligos Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Cibus

CytomX Therapeutics

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

iBio

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kronos Bio

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pyxis Oncology

Quince Therapeutics

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

X4 Pharmaceuticals

Exagen

Jones Trading

HC Wainwright & Co.

Raymond James

Rodman & Renshaw

Morgan Stanley

Comments

Mural Oncology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga